false
0001438943
0001438943
2024-03-29
2024-03-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): March 29, 2024
RANGE
IMPACT, INC.
(Exact
name of registrant as specified in its charter)
Nevada |
|
000-53832 |
|
75-3268988 |
(State
or other jurisdiction |
|
(Commission |
|
(I.R.S.
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
200
Park Avenue, Suite 400 |
|
|
Cleveland,
Ohio |
|
44122 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (216) 304-6556
Not
Applicable
(Former
name or former address, if changed since last report.)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class: |
|
Trading
Symbol |
|
Name
of each exchange on which registered: |
Common
Stock |
|
RNGE |
|
OTC
Markets |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 Results of Operations and Financial Condition
Press
Release
On
March 29, 2024, the Company issued a press release reporting its financial results for the fourth quarter and the full year 2023.
A
copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Item
8.01 Other Events.
The
information set forth in Item 2.02 above is hereby incorporated by reference into this Item 8.01 in its entirety.
The
information in this Item 8.01 (including Exhibit 99.1) is furnished pursuant to Item 8.01 and shall not be deemed to be “filed”
for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required
to be disclosed solely by Regulation FD.
Portions
of this Current Report may constitute “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 that are subject to risks and uncertainties. Although the Company believes any such statements are based on reasonable
assumptions, there is no assurance that the actual outcomes will not be materially different due to a number of factors. Any such statements
are made in reliance on the “safe harbor” protections provided under the Private Securities Litigation Reform Act of 1995.
Additional information about significant risks that may impact the Company is contained in the Company’s filings with the Securities
and Exchange Commission and may be accessed at www.sec.gov. The Company is under no obligation, and expressly disclaims any obligation,
to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Item
9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
RANGE
IMPACT, INC. |
|
|
|
Dated:
March 29, 2024 |
By: |
/s/
Michael Cavanaugh |
|
Name:
|
Michael
Cavanaugh |
|
Title: |
Chief
Executive Officer |
EXHIBIT
INDEX
Exhibit
99.1
Range
Impact Reports 4Q 2023 and Full Year 2023 Financial Results
CLEVELAND,
OHIO – (March 29, 2024) – Range Impact, Inc. (OTC: RNGE) (“Range Impact”), a public impact investing company
dedicated to acquiring, reclaiming and repurposing mine sites in Appalachia, reported its results for the fourth quarter and fiscal year
ended December 31, 2023.
Range
Impact’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 was filed with the Securities and Exchange Commission
on March 29, 2024 and is available for viewing at https://rangeimpact.com/investors/. Since the information provided in this press release
is limited to selected financial and operational information, shareholders and interested parties are encouraged to read Range Impact’s
full Annual Report on Form 10-K available on its website.
Michael
Cavanaugh, Range Impact’s CEO, stated, “I am pleased to announce our seventh consecutive quarter of revenue growth, culminating
in annual revenues of $19.3 million in fiscal 2023 compared to annual revenues of $4.8 million in fiscal 2022. This rapid sales growth
is a direct result of our dedicated employees, the market opportunity for our services, and our unique and focused approach to impact
investing.” Cavanaugh added, “We are in the early stages of our value creation plan and remain dedicated to building a great
business that drives authentic and impactful change throughout Appalachia and other economically-disadvantaged regions of the United
States.”
Fourth
Quarter and Full Year 2023 Financial Highlights
|
○ |
Revenue
| $6,877,519 in 4Q 2023 versus $2,645,661 in 4Q 2022, an increase of $4,231,858, and $19,346,306 for the full year 2023 versus
$4,832,278 for the full year 2022, an increase of $14,514,028. |
|
|
|
|
○ |
Gross
Profit | $1,882,940 in 4Q 2023 versus $970,517 in 4Q 2022, an increase of $912,423, and $6,234,809 for the full year 2023 versus
$1,393,252 for the full year 2022, an increase of $4,841,557. |
|
|
|
|
○ |
Operating
Income (Loss) | $124,023 in 4Q 2023 versus ($35,563) in 4Q 2022, an increase of $159,586, and $1,754,364 for the full year 2023
versus ($1,100,433) for the full year 2022, an increase of $2,854,797. |
|
|
|
|
○ |
Net
Income (Loss) | ($83,022) in 4Q 2023 versus ($61,400) in 4Q 2022, a decrease of ($21,622), and $3,131,055 for the full year 2023
versus ($1,072,176) for the full year 2022, an increase of $4,203,231. |
|
|
|
|
○ |
Adjusted
EBITDA | $1,223,302 in 4Q 2023 versus $561,081 in 4Q 2022, an increase of $662,221, and $3,929,925 for the full year 2023
versus ($202,200) for the full year 2022, an increase of $4,132,125. |
|
|
|
|
○ |
Cash
Flow from Operations | ($636,082) in 4Q 2023 versus ($35,242) in 4Q 2022, a decrease of ($600,840), and $438,637 for the
full year 2023 versus ($603,778) for the full year 2022, an increase of $1,042,415. |
Fourth
Quarter 2023 and Full Year 2023 Consolidated Financial Highlights
| |
4Q
2023 | |
4Q
2022 | |
FY
2023 | |
FY
2022 |
Revenue | |
$ | 6,877,519 | | |
$ | 2,645,661 | | |
$ | 19,346,306 | | |
$ | 4,832,278 | |
Cost
of Goods Sold | |
| 4,994,579 | | |
| 1,675,144 | | |
| 13,111,497 | | |
| 3,439,026 | |
Gross
Profit | |
| 1,882,940 | | |
| 970,517 | | |
| 6,234,809 | | |
| 1,393,252 | |
Operating
Expenses | |
| 1,758,917 | | |
| 1,006,080 | | |
| 4,480,445 | | |
| 2,493,685 | |
Operating
Income (Loss) | |
| 124,023 | | |
| (35,563 | ) | |
| 1,754,364 | | |
| (1,100,433 | ) |
Other
Income | |
| (207,045 | ) | |
| (25,837 | ) | |
| 1,376,691 | | |
| 28,257 | |
Net
Income (Loss) | |
| (83,022 | ) | |
| (61,400 | ) | |
| 3,131,055 | | |
| (1,072,176 | ) |
Non-Cash
Expenses | |
| 1,044,508 | | |
| 600,880 | | |
| 292,953 | | |
| 788,803 | |
Working
Capital Changes | |
| (1,597,568 | ) | |
| (574,722 | ) | |
| (2,985,371 | ) | |
| (320,405 | ) |
Cash
Flow from Operations | |
$ | (636,082 | ) | |
$ | (35,242 | ) | |
$ | 438,637 | | |
$ | (603,778 | ) |
Gross
Profit Margin % | |
| 27.4 | % | |
| 36.7 | % | |
| 32.2 | % | |
| 28.8 | % |
Operating
Profit Margin % | |
| 1.8 | % | |
| -1.3 | % | |
| 9.1 | % | |
| -22.8 | % |
Net
Income Margin % | |
| -1.2 | % | |
| -2.3 | % | |
| 16.2 | % | |
| -22.2 | % |
Cash
Flow from Operations Margin % | |
| -9.2 | % | |
| -1.3 | % | |
| 2.3 | % | |
| -12.5 | % |
Fourth
Quarter 2023 and Full Year 2023 Segmented Financial Highlights
| |
4Q
2023 | |
4Q
2022 | |
FY
2023 | |
FY
2022 |
Revenue | |
| | | |
| | | |
| | | |
| | |
Range
Reclaim | |
$ | 6,491,717 | | |
$ | 2,645,661 | | |
$ | 18,662,111 | | |
$ | 4,832,278 | |
Range
Water | |
| - | | |
| - | | |
| - | | |
| - | |
Range
Security | |
| 385,802 | | |
| - | | |
| 684,195 | | |
| - | |
Range
Land | |
| - | | |
| - | | |
| - | | |
| - | |
Drug
Development | |
| - | | |
| - | | |
| - | | |
| - | |
Corporate | |
| - | | |
| - | | |
| - | | |
| - | |
Total
Revenue | |
$ | 6,877,519 | | |
$ | 2,645,661 | | |
$ | 19,346,306 | | |
$ | 4,832,278 | |
| |
| | | |
| | | |
| | | |
| | |
Gross
Profit | |
| | | |
| | | |
| | | |
| | |
Range
Reclaim | |
$ | 1,639,943 | | |
$ | 970,517 | | |
$ | 5,853,121 | | |
$ | 1,393,252 | |
Range
Water | |
| - | | |
| - | | |
| - | | |
| - | |
Range
Security | |
| 242,997 | | |
| - | | |
| 381,688 | | |
| - | |
Range
Land | |
| - | | |
| - | | |
| - | | |
| - | |
Drug
Development | |
| - | | |
| - | | |
| - | | |
| - | |
Corporate | |
| - | | |
| - | | |
| - | | |
| - | |
Total
Gross Profit | |
$ | 1,882,940 | | |
$ | 970,517 | | |
$ | 6,234,809 | | |
$ | 1,393,252 | |
| |
| | | |
| | | |
| | | |
| | |
Net
Income (Loss) | |
| | | |
| | | |
| | | |
| | |
Range
Reclaim | |
$ | 613,604 | | |
$ | 662,750 | | |
$ | 3,407,546 | | |
$ | 816,469 | |
Range
Water | |
| (16,184 | ) | |
| - | | |
| (69,840 | ) | |
| - | |
Range
Security | |
| 198,548 | | |
| - | | |
| 269,548 | | |
| - | |
Range
Land | |
| (13,134 | ) | |
| - | | |
| (13,134 | ) | |
| - | |
Drug
Development | |
| (104,428 | ) | |
| (130,506 | ) | |
| (458,889 | ) | |
| (470,803 | ) |
Corporate | |
| (761,428 | ) | |
| (593,644 | ) | |
| (4,176 | ) | |
| (1,417,842 | ) |
Total
Net Income (Loss) | |
$ | (83,022 | ) | |
$ | (61,400 | ) | |
$ | 3,131,055 | | |
$ | (1,072,176 | ) |
| |
| | | |
| | | |
| | | |
| | |
Adjusted
EBITDA | |
| | | |
| | | |
| | | |
| | |
Range
Reclaim | |
$ | 1,498,955 | | |
$ | 891,894 | | |
$ | 5,554,210 | | |
$ | 1,266,409 | |
Range
Water | |
| (15,544 | ) | |
| - | | |
| (68,134 | ) | |
| - | |
Range
Security | |
| 201,439 | | |
| - | | |
| 279,873 | | |
| - | |
Range
Land | |
| (13,134 | ) | |
| - | | |
| (13,134 | ) | |
| - | |
Drug
Development | |
| (104,428 | ) | |
| (130,506 | ) | |
| (458,889 | ) | |
| (470,803 | ) |
Corporate | |
| (343,986 | ) | |
| (200,307 | ) | |
| (1,364,001 | ) | |
| (997,806 | ) |
Total
Adjusted EBITDA | |
$ | 1,223,302 | | |
$ | 561,081 | | |
$ | 3,929,925 | | |
$ | (202,200 | ) |
Fourth
Quarter 2023 and Full Year 2023 Reconciliation of Net Income (Loss) to Adjusted EBITDA
| |
4Q
2023 | |
4Q
2022 | |
FY
2023 | |
FY
2022 |
Net
Income (Loss) | |
| | | |
| | | |
| | | |
| | |
Range
Reclaim | |
$ | 613,604 | | |
$ | 662,750 | | |
$ | 3,407,546 | | |
$ | 816,469 | |
Range
Water | |
| (16,184 | ) | |
| - | | |
| (69,840 | ) | |
| - | |
Range
Security | |
| 198,548 | | |
| - | | |
| 269,548 | | |
| - | |
Range
Land | |
| (13,134 | ) | |
| - | | |
| (13,134 | ) | |
| - | |
Drug
Development | |
| (104,428 | ) | |
| (130,506 | ) | |
| (458,889 | ) | |
| (470,803 | ) |
Corporate | |
| (761,428 | ) | |
| (593,644 | ) | |
| (4,176 | ) | |
| (1,417,842 | ) |
Total
Net Income (Loss) | |
$ | (83,022 | ) | |
$ | (61,400 | ) | |
$ | 3,131,055 | | |
$ | (1,072,176 | ) |
| |
| | | |
| | | |
| | | |
| | |
Interest | |
| | | |
| | | |
| | | |
| | |
Range
Reclaim | |
$ | 177,154 | | |
$ | 25,756 | | |
$ | 376,898 | | |
$ | 54,397 | |
Range
Water | |
| - | | |
| - | | |
| - | | |
| - | |
Range
Security | |
| - | | |
| - | | |
| 224 | | |
| - | |
Range
Land | |
| - | | |
| - | | |
| - | | |
| - | |
Drug
Development | |
| - | | |
| - | | |
| - | | |
| - | |
Corporate | |
| 84,662 | | |
| 77 | | |
| 128,795 | | |
| 26,776 | |
Total
Interest | |
$ | 261,816 | | |
$ | 25,833 | | |
$ | 505,917 | | |
$ | 81,173 | |
| |
| | | |
| | | |
| | | |
| | |
Taxes | |
| | | |
| | | |
| | | |
| | |
Range
Reclaim | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Range
Water | |
| - | | |
| - | | |
| - | | |
| - | |
Range
Security | |
| - | | |
| - | | |
| - | | |
| - | |
Range
Land | |
| - | | |
| - | | |
| - | | |
| - | |
Drug
Development | |
| - | | |
| - | | |
| - | | |
| - | |
Corporate | |
| - | | |
| - | | |
| - | | |
| - | |
Total
Taxes | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Depreciation | |
| | | |
| | | |
| | | |
| | |
Range
Reclaim | |
$ | 708,197 | | |
$ | 203,388 | | |
$ | 1,769,766 | | |
$ | 395,543 | |
Range
Water | |
| 640 | | |
| - | | |
| 1,706 | | |
| - | |
Range
Security | |
| 2,891 | | |
| - | | |
| 10,101 | | |
| - | |
Range
Land | |
| - | | |
| - | | |
| - | | |
| - | |
Drug
Development | |
| - | | |
| - | | |
| - | | |
| - | |
Corporate | |
| - | | |
| - | | |
| - | | |
| - | |
Total
Depreciation | |
$ | 711,728 | | |
$ | 203,388 | | |
$ | 1,781,573 | | |
$ | 395,543 | |
| |
| | | |
| | | |
| | | |
| | |
Non-Cash
Adjustments | |
| | | |
| | | |
| | | |
| | |
Range
Reclaim | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Range
Water | |
| - | | |
| - | | |
| - | | |
| - | |
Range
Security | |
| - | | |
| - | | |
| - | | |
| - | |
Range
Land | |
| - | | |
| - | | |
| - | | |
| - | |
Drug
Development | |
| - | | |
| - | | |
| - | | |
| - | |
Corporate | |
| 332,780 | | |
| 393,260 | | |
| (1,488,620 | ) | |
| 393,260 | |
Total
Non-Cash Adjustments | |
$ | 332,780 | | |
$ | 393,260 | | |
$ | (1,488,620 | ) | |
$ | 393,260 | |
| |
| | | |
| | | |
| | | |
| | |
Adjusted
EBITDA | |
| | | |
| | | |
| | | |
| | |
Range
Reclaim | |
$ | 1,498,955 | | |
$ | 891,894 | | |
$ | 5,554,210 | | |
$ | 1,266,409 | |
Range
Water | |
| (15,544 | ) | |
| - | | |
| (68,134 | ) | |
| - | |
Range
Security | |
| 201,439 | | |
| - | | |
| 279,873 | | |
| - | |
Range
Land | |
| (13,134 | ) | |
| - | | |
| (13,134 | ) | |
| - | |
Drug
Development | |
| (104,428 | ) | |
| (130,506 | ) | |
| (458,889 | ) | |
| (470,803 | ) |
Corporate | |
| (343,986 | ) | |
| (200,307 | ) | |
| (1,364,001 | ) | |
| (997,806 | ) |
Total
Adjusted EBITDA | |
$ | 1,223,302 | | |
$ | 561,081 | | |
$ | 3,929,925 | | |
$ | (202,200 | ) |
“Our
reclamation services business has been the primary driver of our revenue growth over the past two years. We are pleased to see the positive
results coming from the successful acquisition and integration of Range Environmental Resources and Range Natural Resources, which provide
traditional mine reclamation and incidental mining services, and Collins Building & Contracting which provides abandoned mine land
reclamation,” stated Cavanaugh. “As part of our long-term growth strategy, during 1Q 2024 we have repositioned our Range
Environmental business to focus on larger, longer-term mine projects, transitioned our Range Natural mining operations to a subcontractor
model to achieve greater scale with less capital investment, and allocated more employees and equipment to several recently-awarded and
more seasonal abandoned mine land jobs through Collins Building.”
“As
a result of these strategic initiatives, we anticipate revenue for 1Q 2024 to be approximately $3.5 million, which compares favorably
to revenue for 1Q 2023 of $3.0 million, and a full year 2024 revenue target similar to full year 2023 levels.” Cavanaugh added,
“We are very excited about the progress we are making to develop long-term revenue streams for our company, and look forward to
sharing future updates with shareholders throughout the upcoming year.”
Non-GAAP
Financial Information
In
addition to our results under Generally Accepted Accounting Principles (“GAAP”), in this release we also present certain
other supplemental measures of financial performance that are not required by or presented in accordance with GAAP, including Adjusted
Earnings Before Interest Taxes Depreciation and Amortization (“Adjusted EBITDA”). We calculate Adjusted EBITDA as net income
(loss) before interest expense, income tax expense, depreciation and amortization, non-cash stock-based compensation expenses related
to restricted stock grants and stock options issued to directors and employees and consultants, and any one-time non-recurring items.
Adjusted EBITDA is one of the primary metrics used by management to evaluate our financial performance, analyze the effectiveness of
our business strategies, and make budgeting and capital allocation decisions. However, this non-GAAP measure does have certain limitations
and should not be considered as an alternative to net income (loss), earnings (loss) per share or any other performance measures derived
in accordance with GAAP.
About
Range Impact, Inc.
Headquartered
in Cleveland, Ohio, Range Impact is a public company (OTC: RNGE) dedicated to improving the health and wellness of people and the planet
through a novel and innovative approach to impact investing. Range Impact owns and operates several complementary operating businesses
focused on developing long-term solutions to environmental, social, and health challenges, with a particular focus on acquiring, reclaiming
and repurposing mine sites and other undervalued land in economically disadvantaged communities throughout Appalachia. Range Impact takes
an opportunistic approach to impact investing by leveraging its competitive advantages and looking at solving old problems in new ways.
Range Impact seeks to thoughtfully allocate its capital into strategic opportunities that are expected to make a positive impact on the
people-planet ecosystem and generate strong investment returns for its shareholders.
Notice
Regarding Forward-Looking Statements
This
press release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933,
as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely
historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the
future. Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors that could
cause actual outcomes and results to be materially different from those indicated in such statements. Such factors include, among others,
the inherent uncertainties associated with new projects and development stage companies, timing of clinical trials and product development,
business strategy and new lines of business. These forward-looking statements are made as of the date of this press release, and we assume
no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected
in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors
should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report
on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with
the Securities and Exchange Commission.
Range
Impact, Inc.
Investor
Relations
P:
+1 (216) 304-6556
E:
ir@rangeimpact.com
W:
www.rangeimpact.com
v3.24.1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Malachite Innovations (PK) (USOTC:MLCT)
Historical Stock Chart
From Apr 2024 to May 2024
Malachite Innovations (PK) (USOTC:MLCT)
Historical Stock Chart
From May 2023 to May 2024